SenoClaire
3D Breast Tomosynthesis

More clarity. More confidence. Low dose\(^1\).

Available on Senographe\(^*\) Essential

GE’s SenoClaire\(^*\) breast tomosynthesis is a three-dimensional imaging technology that uses a low-dose short X-ray sweep around the compressed breast with only nine exposures. This imaging technique is designed to separate the tissues and to reduce the overlapping of structures, which represents a limiting factor in standard 2D mammography.
See more clearly

- The SenoClaire detector delivers high DQE at low dose for visualizing microcalcifications without binning, a process that regroups pixels for faster readout speeds and improved signal-to-noise ratios, but with reduced image quality.

- Step-and-shoot tube motion preserves microcalcification sharpness and avoids image blur, since the tube makes a complete stop for each of the nine exposures.

- An anti-scatter solution designed for tomosynthesis, the SenoClaire grid in 3D reduces scattered radiation while preserving dose and performance.

- SenoClaire uses ASiR\textsuperscript{DBT}, a calcification artifact correction iterative reconstruction algorithm that delivers off-plane images much improved in terms of both in-plane and out-of-plane artifacts versus the traditional Filtered Back Projection (FBP) algorithm.

Screen more effectively

Due to its low dose and non-inferior clinical accuracy\textsuperscript{2}, SenoClaire has the potential to replace digital mammography exams in screening to detect breast cancer.

NOTE: In Canada, SenoClaire is not approved for screening using DBT.
Care with confidence

Because GE builds the Senographe with upgradability in mind, you can easily expand the system as your needs and capabilities grow. SenoClaire 3D breast tomosynthesis, stereotaxy, or SenoBright® contrast enhanced spectral mammography are fully compatible with any Senographe Essential and Senographe Care. It’s an excellent balance of precision and performance, so you can be confident in your investment.

Connect with compatibility

SenoClaire images are compatible with major PACS providers (with local variability), allowing integration into your environment and helping you make optimal use of your investment. With the IDI MammoWorkstation, radiologists can smoothly navigate through the DBT dataset using dedicated 2D/3D hanging protocols and specific ergonomic features:

- Straightforward visual identification of all series of tomosynthesis planes and slabs
- Dedicated tools to review tomosynthesis data sets: cine loop, bookmarks, breast localizer, breast height ruler
- V-Preview, a 2D image generated from the raw DBT projection data that helps the user get an overview of the entire stack, before examining the planes in the corresponding DBT set.

V-Preview is a navigation tool, is not intended for diagnostic use. V-Preview has not been shown to be equivalent to FFDM. It is not intended to replace the FFDM view.
It's a requirement of dose performance that patient X-ray dose be kept as low as reasonably acceptable. The dose of a SenoClaire 3D view is equivalent to that of a 2D standard acquisition of the same view.

- SenoClaire uses ASIR®, a calcification artifact correction iterative reconstruction algorithm that delivers off-plane images much improved in terms of both in-plane and out-of-plane artifacts versus the traditional Filtered Back Projection (FBP) algorithm.
- SenoClaire’s 3D MLO sequence requires only nine exposures with an even distribution of the dose.
- The SenoClaire grid in 3D reduces scattered radiation while preserving dose and performance.
- The dual-track X-ray tube (Mo/Rh) delivers optimized X-ray spectra to penetrate the breast based on breast density and compressed breast thickness. Automatic Optimization of Parameters (AOP) helps you identify the densest breast regions and automatically selects the appropriate anode, filter, kV and mAs to ensure repeatable image quality at optimized radiation dose.

Data subject to change.
A General Electric company, doing business as GE Healthcare

1. The dose of a SenoClaire 3D view is equivalent to that of a 2D standard acquisition of the same view.
2. GE190-004 BIE (Blinded Imaging Evaluation) study - US. A Multicenter Study to Test the Non-Inferiority of Digital Breast Tomosynthesis Compared to FFDM as measured by the area under the Receiver Operating Characteristic (ROC) curve in Detecting Breast Cancer. A summary of this study can be found on the U.S. Food and Drug Administration website under the following reference: SenoClaire P130020.

*GE, GE monogram, Senographe, SenoClaire and ASIR, are trademarks of General Electric Company. SenoClaire may not be commercially available in all regions. Please check with your local representative.

© 2014 Copyright GE Healthcare - HCS DGS WH BC 07 14 1 JB22539USd#I